{"nctId":"NCT00535782","briefTitle":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","startDateStruct":{"date":"2007-10-31","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":132,"armGroups":[{"label":"TCZ + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Tocilizumab","Drug: Methotrexate"]},{"label":"Placebo + MTX","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Tocilizumab","Drug: Placebo","Drug: Methotrexate"]}],"interventions":[{"name":"Tocilizumab","otherNames":["RoActemra","Actemra"]},{"name":"Placebo","otherNames":[]},{"name":"Methotrexate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, 18-75 years of age\n* rheumatoid arthritis (RA) of \\>6 months duration\n* able to receive outpatient treatment\n* on methotrexate for at least 12 weeks before entering study, at a stable dose of 7.5-25 mg/week for the last 8 weeks\n* oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) permitted, if at a stable dose for 4 weeks before study start\n\nExclusion Criteria\n\n* major surgery (including joint surgery) within 8 weeks prior to screening, or planned surgery within 6 months after entering study\n* history of, or current inflammatory joint disease or rheumatic autoimmune disease other than RA\n* inadequate response to anti-tumor necrosis factor (TNF) agent during the 6 months prior to baseline, or inadequate response to \\>2 anti-TNF agents\n* initiation of treatment with lipid lowering agents within 12 weeks prior to baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers","description":"Small LDL particles are associated with an increased risk of cardiovascular disease: more of these small particles lead to a greater risk. The concentration of fasting small LDL particles was determined using the Nuclear Magnetic Resonance (NMR) methodology.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"737.79","spread":"467.097"},{"groupId":"OG001","value":"792.78","spread":"392.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"768.04","spread":"628.281"},{"groupId":"OG001","value":"777.71","spread":"394.527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.73","spread":"368.273"},{"groupId":"OG001","value":"22.41","spread":"237.476"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Small Low Density Lipoprotein (sLDL) Particle Numbers","description":"Small LDL particles are associated with an increased risk of cardiovascular disease: more of these small particles lead to a greater risk. The concentration of fasting small LDL particles was determined using the Nuclear Magnetic Resonance (NMR) methodology.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"737.79","spread":"467.097"},{"groupId":"OG001","value":"792.78","spread":"392.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"792.78","spread":"605.485"},{"groupId":"OG001","value":"801.78","spread":"398.910"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.03","spread":"367.786"},{"groupId":"OG001","value":"32.41","spread":"250.576"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in Aortic Pulse Wave Velocity (PWV)","description":"Aortic (central) arterial stiffness was assessed with Pulse Wave Analysis (PWA) of the radial artery and carotid-femoral PWV using applanation tonometry after the patient had rested in a supine position for at least 10 minutes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"1.970"},{"groupId":"OG001","value":"9.01","spread":"2.519"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.98","spread":"2.337"},{"groupId":"OG001","value":"8.85","spread":"2.014"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"1.946"},{"groupId":"OG001","value":"-0.20","spread":"1.792"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Adverse Events (AEs)","description":"A severe AE is an event in which the intensity of the event results in an inability to work or perform normal daily activity.\n\nA Serious AE is fatal, life-threatening, requires in-patient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant or requires intervention to prevent one of the above outcomes.\n\nAEs of special interest include infection, gastrointestinal, infusion reaction (occurring during or within 24 hours of infusion), hepatic disorder, myocardial infarction and stroke.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 12 in Aortic Pulse Wave Velocity (PWV)","description":"Aortic (central) arterial stiffness was assessed with Pulse Wave Analysis (PWA) of the radial artery and carotid-femoral PWV using applanation tonometry after the patient had rested in a supine position for at least 10 minutes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"1.970"},{"groupId":"OG001","value":"9.01","spread":"2.519"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.94","spread":"2.510"},{"groupId":"OG001","value":"8.39","spread":"1.836"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"1.970"},{"groupId":"OG001","value":"-0.68","spread":"1.741"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":70},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Diarrhoea","Bronchitis","Rheumatoid arthritis"]}}}